AIDE Technology Platform

Quince’s highly differentiated autologous intracellular drug encapsulation (AIDE) technology platform is designed to enable the delivery of a therapeutic using a patient’s own blood.

By leveraging a patient’s own biology to deliver a therapeutic encapsulated in autologous red blood cells, our proprietary AIDE technology is believed to fundamentally alter a drug’s pharmacokinetics to allow for chronic administration for the potential treatment of rare diseases. This unique autologous delivery approach holds the potential to provide life-changing innovative therapeutics to address underserved rare disease patients with high unmet medical need.

Quince’s Phase 3 lead asset, EryDex, utilizes this AIDE technology platform and is designed to optimize the pharmacokinetics and biodistribution of dexamethasone sodium phosphate (DSP) by using a patient’s own red blood cells to deliver the sustained therapy over a once monthly treatment period. Designed for the potential treatment of a rare neurodegenerative disease, Ataxia-Telangiectasia (A-T), we plan to advance a single global Phase 3 clinical trial entitled NEAT (#IDEAT-04-2022 – Neurologic Effects of EryDex on Subjects with AT) to evaluate the neurological effects of EryDex on patients with A-T. Enrollment for the Phase 3 NEAT trial is anticipated to begin in the second quarter of 2024.

Highly Differentiated and Proprietary AIDE Technology Platform

AIDE – Autologous Intracellular Drug Encapsulation

One-touch, fully automated, and sterile Autologous Intracellular Drug Encapsulation (AIDE) device

Designed to deliver therapeutic in patient’s own red blood cells – distinct from standard cell or gene therapy

Flexible technology designed to deliver wide range of therapeutics from small and large molecules to biologics – with minimal CMC costs

CE mark in Europe with strong patent protections and IP exclusivity until at least 2034 globally & 2035 in U.S. – without patent term adjustment or extension

With high barriers to competitive entry, Quince’s proprietary AIDE technology platform is the result of more than $100 million of investment and 20+ years of innovation to develop a unique drug delivery technology that leverages a patient’s own biology to deliver rare disease therapies.

Highly Differentiated and Proprietary Drug/Device Combination

Quince’s AIDE technology platform consists of a specialized system called the Red Cell Loader (RCL), a sterile single use treatment kit called the EryKit, and process solutions utilized in the point-of-care treatment.

RCL Machine

Red Cell Loader (RCL)

The RCL is a proprietary CE marked non-invasive device that allows blood processing at the point of care. It automates the AIDE process technology by handling the blood, drug, and processing solutions with the use of EryKit. The system has a user-friendly touch screen interface made up of three microprocessor circuit boards, two main boards, and an independent protective board as control.

EryKit Treatment Consumables

EryKit is a CE marked medical device. It provides the essential single-use components for loading human red blood cells (RBCs) with variety of therapeutics, ranging from small to large molecules, as well as biologics, by using the RCL. The EryKit contains a sterile, single use, pyrogen-free disposable blood tubing system equipped with a centrifuge, hemoconcentrator filter, bags, organizer cassette, and other accessories.

EryKit Consumables

AIDE Technology Fully Automated at Patient Point-of-Care

AIDE Technology at Point-of-Care

Patient’s own blood collected and loaded into device using consumable treatment kit for fully automated and sterile processing

AIDE processes red blood cells to encapsulate therapeutic of interest – dexamethasone sodium phosphate (DSP) in case of lead asset EryDex

Result of the process is DSP loaded red blood cells that are washed, isolated, and prepared – no gene editing or conditioning regimen required

Proprietary process results in DSP encapsulated in autologous red blood cells that is then infused into patient

Approximately two-hour process designed for monthly outpatient administration, if approved

Designed to fundamentally alter pharmacokinetics and biodistribution of DSP to allow for sustained therapy – mitigating chronic toxicity associated with long-term steroid use